Results 51 to 60 of about 2,329 (147)

Isolated Mild Hyperemia Identified by Intestinal Ultrasound Is Associated With Adverse Outcomes in Inflammatory Bowel Disease

JCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Background Increased bowel wall thickness (BWT) measured by intestinal ultrasound (IUS) is the most predictive sonographic parameter of endoscopic disease activity in Crohn's disease (CD) and ulcerative colitis (UC). The clinical significance of hyperemia in the absence of increased BWT has yet to be delineated.
Noa Krugliak Cleveland, Khushi S. Bhondwe, Charlotte M. Duty, Evan N. Fear, Tessa George, Qamar Nisa Ayoub, Benjamin D. McDonald, Amelia Kellar, David T. Rubin   +8 more
wiley   +1 more source

Efficacy of Advanced Medical Therapies in Patients With Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta‐Analysis

JCC Plus, Volume 1, Issue 5, September 2026.
This systematic review and meta‐analysis quantify absolute outcome differences of advanced therapies in moderate‐to‐severe ulcerative colitis, demonstrating significant benefits in clinical, endoscopic, and histological remission, and establishing a benchmark for evaluating novel or non‐pharmacological treatment strategies.
E. Visser, I. D. van Dijk, G. L. Burchell, W. A. Bemelman, G. R. D'Haens, C. J. Buskens   +5 more
wiley   +1 more source

Concentration‐QTc Modeling of Ozanimod’s Major Active Metabolites in Adult Healthy Subjects

CPT: Pharmacometrics & Systems Pharmacology, 2021
Ozanimod, approved by regulatory agencies in multiple countries for the treatment of adults with relapsing multiple sclerosis, is a sphingosine 1‐phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P receptor subtypes 1 ...
Emily Briggs, Sunny Chapel, Peijin Zhang, Maria Palmisano, Jonathan Q. Tran   +4 more
doaj   +1 more source

Inflammatory Bowel Disease: Mechanisms and Therapeutic Advances

MedComm, Volume 7, Issue 9, September 2026.
Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is a rising, multifactorial chronic disorder driven by dysregulated mucosal immunity in genetically susceptible individuals and influenced by environmental and microbial factors.
Andrea Papait, Anna Cargnoni, Franco Scaldaferri, Loris Lopetuso, Antonietta Rosa Silini, Ornella Parolini   +5 more
wiley   +1 more source

Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 6, Page 729-747, September 2026.
The gut microbiome modulates ulcerative colitis pharmacotherapy through microbial drug metabolism, immune regulation and altered drug bioavailability. Microbial composition influences response to aminosalicylates, corticosteroids, immunomodulators, biologics and small molecules, while microbiome‐targeted therapies show emerging promise.
Kate Collins, Srinivas Kamath, Rachel H. Davis, Samuel P. Costello, Robert V. Bryant, Alice S. Day, Paul Joyce   +6 more
wiley   +1 more source

The Burden of Viral Respiratory Infections in Immunosuppressed Inflammatory Bowel Disease Patients

JGH Open, Volume 10, Issue 8, August 2026.
ABSTRACT Background and Aim Due to the increasing immunosuppressant use in inflammatory bowel disease (IBD) and the risk of serious infections, this study investigates the prevalence and risk factors of respiratory pathogen detection in this population to improve patient care.
D. Huynh, E. Khoo, A. Shanmuga Anandan, J. Begun   +3 more
wiley   +1 more source

Selective S1P Receptor Modulation in Multiple Sclerosis Alters CXCL13:CXCR5-Associated Immune Activities Without Impacting Anti-SARS-CoV-2 Immunity

Neurology and Therapy
Introduction Sphingosine-1-phosphate receptor (S1PR) modulators are effective therapies for multiple sclerosis (MS) that block lymphocyte egress from secondary lymphoid organs.
Andrea Harrer, Richard F. Radlberger, Beate Buchegger, Brooke Slade, Thomas Haybaeck, Hannes Oberkofler, Konstantin E. Thiel, Ferdinand Otto, Tobias Moser, Peter Wipfler   +9 more
doaj   +1 more source

A Care Pathway for the Treatment of IBD Reduces Healthcare Costs and Is Cost‐Effective: Results of the Multicentre IBD Value Study

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 3, Page 313-325, August 2026.
This study provides real‐world evidence that implementing an advanced therapy care pathway for patients with IBD leads to significant healthcare cost savings without compromising quality of life. These findings support broader implementation of care pathways in the management of patients with chronic conditions to optimise care delivery and resource ...
Elyke H. Visser, Martijn. A. Oude Voshaar, Reinier C. A. van Linschoten, Alexander G. L. Bodelier, Claire Fitzpatrick, Vincent de Jonge, Hestia Vermeulen, K. Evelyne Verweij, Sanne van der Wiel, Daniëlle van der Horst, C. Janneke van der Woude, R. L. West, D. van Noord   +12 more
wiley   +1 more source

Bridging the Pregnancy Knowledge Gap: A Real‐World Analysis of Medication Use and Drug–Drug Interaction Risk in Crohn's Disease and Multiple Sclerosis

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT The exclusion of pregnant individuals from clinical trials has resulted in a significant medical knowledge gap for this population. Leveraging real‐world data (RWD) provides a critical window into the prevalence and use of medications during pregnancy.
Jacqueline Williams, Rucha Sane, Amita Joshi, Kit Wun Kathy Cheung, Bianca Vora   +4 more
wiley   +1 more source

Chemical structure of ozanimod (RPC1063) and RP-101075.

, 2018
Chemical structure of ozanimod (RPC1063) and RP-101075.
Bryan Clemons (5047685), Matthew E. Stokes (5047688), Gregory J. Opiteck (3087825), Fiona L. Scott (5047676), Marcos W. Steinberg (49347), Robert Peach (5047679), Kristen R. Taylor Meadows (5047682)   +6 more
core   +1 more source